The Late-Breaking Abstracts have been selected for the Society of
Gynecologic Oncology’s 2016 Annual Meeting on Women’s Cancer. The most
current data from the following studies will be presented on
Monday,
March 21:
- Analysis of the neoadjuavant arm of CHORUS: A response after three
cycles of first-line platinum chemotherapy in advanced ovarian cancer
- A prospective randomized trial comparing colorimetric and
fluorescent imaging for pelvic sentinel lymph node mapping in
endometrial cancer
- The preliminary results of a phase II study: PD-1 blockade in
mismatch repair–deficient, recurrent, or persistent endometrial cancer
- NRG Oncology/Gynecologic Oncology 186K: The final results of a
randomized phase II study of NCI-supplied cabozantinib vs. weekly
paclitaxel in the treatment of persistent or recurrent epithelial
ovarian, fallopian tube, or primary peritoneal cancer
- NRG/GOG study showing disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival
- An NRG study on a phase III trial of bevacizumab with IV vs. IP
chemotherapy for ovarian, fallopian tube, and peritoneal carcinoma
- Patient-reported outcomes in GOG 252: An NRG Oncology Study of IV
vs. IP chemotherapy for ovarian, fallopian, or peritoneal carcinoma
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.